RxDoctor Payments Data

Peter Wagner, DO

Cardiovascular Disease · Greenville, NCNPI 1598734196

Payments from drug & device makers

$19,807in general payments, 2019–2025

Across 41 payments — averaging $483.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$19K
  • Pfizer$280
  • Corvista Health, Inc.$213
  • Boston Scientific$175
  • Amgen$91
  • E.r. Squibb & Sons, L.L.C.$53
  • plus $145 from 6 others

What the payments were for

  • Food & beverage$957100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,807 in reported general payments places this provider in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$149,882
Medicare patients
1,289
Services billed
2,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban556$492,922
EntrestoSacubitril/Valsartan180$162,712
Repatha SureclickEvolocumab93$76,476
JardianceEmpagliflozin24$19,265
Ranolazine ErRanolazine250$16,728
MultaqDronedarone Hcl14$14,805
Repatha SyringeEvolocumab14$11,698
Praluent PenAlirocumab26$11,345
FarxigaDapagliflozin Propanediol14$10,132
BrilintaTicagrelor20$9,530
Metoprolol Succinate435$5,589
Atorvastatin Calcium352$4,075
Potassium Chloride140$3,710
Bumetanide64$2,971
Isosorbide Mononitrate ErIsosorbide Mononitrate229$2,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$280$492,922556 claims
NovartisEntresto$18,850$162,712180 claims
AstraZenecaFarxiga, Brilinta$12$19,66234 claims
Sanofi-aventis U.S. LLCMultaq$23$14,80514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →